Volitionrx LTD VNRX
Institutional shares held
17.8 Million
41K
calls
100
puts
Total value of holdings
$11.2M
$25K
calls
$0
puts
Market Cap
$39M
57,297,000
Shares Out.
Institutional ownership
31.03%
# of Institutions
26
We take great care to ensure that the data presented and summarized in this overview for VOLITIONRX LTD is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VNRX
View all-
Armistice Capital, LLC New York, NY9MShares$6.12 Million0.09% of portfolio
-
Lagoda Investment Management, L.P. New York, NY6.1MShares$4.14 Million2.11% of portfolio
-
Geode Capital Management, LLC Boston, MA730KShares$496,7040.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA637KShares$432,9330.0% of portfolio
-
Black Rock Inc. New York, NY516KShares$350,9290.0% of portfolio
-
Cowen Prime Advisors LLC179KShares$121,5410.09% of portfolio
-
Silverberg Bernstein Capital Management LLC Armonk, NY143KShares$96,9800.08% of portfolio
-
State Street Corp Boston, MA124KShares$84,2670.0% of portfolio
-
Ubs Group Ag116KShares$78,7390.0% of portfolio
-
Northern Trust Corp Chicago, IL89.3KShares$60,7210.0% of portfolio
Latest Institutional Activity in VNRX
Top Purchases
Top Sells
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
Insider Transactions at VNRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2024
|
Cameron John Reynolds President and CEO |
BUY
Open market or private purchase
|
Direct |
139,811
+6.19%
|
$0
$0.57 P/Share
|
|
Dec 09
2024
|
Jacob Vincent Micallef Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
43,691
+9.97%
|
$0
$0.57 P/Share
|
|
Dec 09
2024
|
Timothy I Still |
BUY
Open market or private purchase
|
Direct |
87,382
+5.55%
|
$0
$0.57 P/Share
|
|
Dec 09
2024
|
Guy Archibald Innes |
BUY
Open market or private purchase
|
Direct |
174,764
+22.07%
|
$0
$0.57 P/Share
|
|
Dec 01
2024
|
Salvatore Thomas Butera CEO, Volition Veterinary |
BUY
Grant, award, or other acquisition
|
Direct |
16,871
+5.43%
|
-
|
|
Dec 01
2024
|
Andrew Retter Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,365
+6.84%
|
-
|
|
Dec 01
2024
|
Terig Hughes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,683
+3.26%
|
-
|
|
Dec 01
2024
|
Kim Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
8,648
+10.15%
|
-
|
|
Dec 01
2024
|
Ann Louise Batchelor Group Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,143
+10.28%
|
-
|
|
Dec 01
2024
|
Alan Colman |
BUY
Grant, award, or other acquisition
|
Direct |
12,972
+5.33%
|
-
|
|
Dec 01
2024
|
Jasmine Kway CEO, Singapore Volition |
BUY
Grant, award, or other acquisition
|
Direct |
15,169
+8.37%
|
-
|
|
Dec 01
2024
|
Ethel Rubin |
BUY
Grant, award, or other acquisition
|
Direct |
8,648
+26.78%
|
-
|
|
Dec 01
2024
|
Gael Forterre Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,828
+2.98%
|
-
|
|
Dec 01
2024
|
Guy Archibald Innes |
BUY
Grant, award, or other acquisition
|
Direct |
17,296
+3.76%
|
-
|
|
Dec 01
2024
|
Nicholas Plummer GC, Volition Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
11,527
+6.52%
|
-
|
|
Dec 01
2024
|
Rodney Gerard Rootsaert Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
7,302
+5.13%
|
-
|
|
Nov 06
2024
|
Timothy I Still |
BUY
Grant, award, or other acquisition
|
Direct |
1,400,000
+45.83%
|
-
|
|
Oct 04
2024
|
Jacob Vincent Micallef Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,200
-1.46%
|
$0
$0.88 P/Share
|
|
Oct 04
2024
|
Nicholas Plummer GC, Volition Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
8,146
-5.04%
|
$0
$0.88 P/Share
|
|
Oct 04
2024
|
Gael Forterre Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,433
-3.44%
|
$0
$0.88 P/Share
|
Last 12 Months Summary
Buy / Acquisition
3.88M
Shares
From
25
Insiders
| Grant, award, or other acquisition | 2.89M shares |
|---|---|
| Bona fide gift | 400K shares |
| Open market or private purchase | 596K shares |
Sell / Disposition
497K
Shares
From
8
Insiders
| Bona fide gift | 400K shares |
|---|---|
| Payment of exercise price or tax liability | 77.1K shares |
| Open market or private sale | 20K shares |